Work

Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients with Episodic Migraine After Including CHALLENGE-MIG Trial (P9-12.007)

Year: 2025

Type: article

Study designs: Systematic Review, Meta-Analysis

Source: Neurology

DOI: 10.1212/wnl.0000000000210714

Authors: Jessica Ailani, Pranav Gandhi, Anjana Lalla, Peter McAllister, Tanya Bilchik, Stephanie Nahas, David Rowe, Cristiano Piron, Kari Kelton, Rashmi Halker Singh

Institutions: MedStar Health, AbbVie (United States), New England Institute for Neurology and Headache, Yale University, Thomas Jefferson University, Medical Decision Modeling (United States), Mayo Clinic

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409226179

FWCI:

Cites:

Cited by:

Related to: 10